192 related articles for article (PubMed ID: 21788094)
1. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.
Chen HH; Yan JJ; Chen WC; Kuo MT; Lai YH; Lai WW; Liu HS; Su WC
Lung Cancer; 2012 Feb; 75(2):228-34. PubMed ID: 21788094
[TBL] [Abstract][Full Text] [Related]
2. Expression of the copper transporters hCtr1, ATP7A and ATP7B is associated with the response to chemotherapy and survival time in patients with resected non-small cell lung cancer.
Yang T; Chen M; Chen T; Thakur A
Oncol Lett; 2015 Oct; 10(4):2584-2590. PubMed ID: 26622894
[TBL] [Abstract][Full Text] [Related]
3. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).
Li ZH; Qiu MZ; Zeng ZL; Luo HY; Wu WJ; Wang F; Wang ZQ; Zhang DS; Li YH; Xu RH
J Transl Med; 2012 Feb; 10():21. PubMed ID: 22304828
[TBL] [Abstract][Full Text] [Related]
4. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
[TBL] [Abstract][Full Text] [Related]
5.
Li YQ; Zhang XY; Chen J; Yin JY; Li XP
J Cancer Res Ther; 2018; 14(4):881-886. PubMed ID: 29970670
[TBL] [Abstract][Full Text] [Related]
6. Correlation of Expression Levels of Copper Transporter 1 and Thymidylate Synthase with Treatment Outcomes in Patients with Advanced Non-small Cell Lung Cancer Treated with S-1/Carboplatin Doublet Chemotherapy.
Konishi M; Imai A; Fujii M; Sugimoto K; Katakami N; Imai Y; Kamoshida S
Asian Pac J Cancer Prev; 2018 Feb; 19(2):435-441. PubMed ID: 29479997
[TBL] [Abstract][Full Text] [Related]
7. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
Martinez-Balibrea E; Martínez-Cardús A; Musulén E; Ginés A; Manzano JL; Aranda E; Plasencia C; Neamati N; Abad A
Int J Cancer; 2009 Jun; 124(12):2905-10. PubMed ID: 19296535
[TBL] [Abstract][Full Text] [Related]
8. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
10. A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients.
Mo H; Hao X; Liu Y; Wang L; Hu X; Xu J; Yang S; Xing P; Shi Y; Jia B; Wang Y; Li J; Wang H; Wang Z; Sun Y; Shi Y
Cancer Med; 2016 Jun; 5(6):1116-24. PubMed ID: 26993156
[TBL] [Abstract][Full Text] [Related]
11. Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity.
Cui H; Zhang AJ; McKeage MJ; Nott LM; Geraghty D; Guven N; Liu JJ
J Inorg Biochem; 2017 Dec; 177():249-258. PubMed ID: 28551160
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of MAC30 is Resistant to Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Chen R; Fen Y; Lin X; Ma T; Cai H; Ding H
Technol Cancer Res Treat; 2016 Dec; 15(6):815-820. PubMed ID: 26376695
[TBL] [Abstract][Full Text] [Related]
13. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
[TBL] [Abstract][Full Text] [Related]
14. The roles of copper transporters in cisplatin resistance.
Kuo MT; Chen HH; Song IS; Savaraj N; Ishikawa T
Cancer Metastasis Rev; 2007 Mar; 26(1):71-83. PubMed ID: 17318448
[TBL] [Abstract][Full Text] [Related]
15. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).
Song L; Li Y; Li W; Wu S; Li Z
J Cell Biochem; 2014 Jul; 115(7):1234-42. PubMed ID: 24038379
[TBL] [Abstract][Full Text] [Related]
16. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.
Kim ES; Tang X; Peterson DR; Kilari D; Chow CW; Fujimoto J; Kalhor N; Swisher SG; Stewart DJ; Wistuba II; Siddik ZH
Lung Cancer; 2014 Jul; 85(1):88-93. PubMed ID: 24792335
[TBL] [Abstract][Full Text] [Related]
17. FGF13 enhances resistance to platinum drugs by regulating hCTR1 and ATP7A via a microtubule-stabilizing effect.
Yu H; Wang H; Qie A; Wang J; Liu Y; Gu G; Yang J; Zhang H; Pan W; Tian Z; Wang C
Cancer Sci; 2021 Nov; 112(11):4655-4668. PubMed ID: 34533854
[TBL] [Abstract][Full Text] [Related]
18. Role of copper transporters in resistance to platinating agents.
Rabik CA; Maryon EB; Kasza K; Shafer JT; Bartnik CM; Dolan ME
Cancer Chemother Pharmacol; 2009 Jun; 64(1):133-42. PubMed ID: 18998134
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic basis for overcoming platinum resistance using copper chelating agents.
Liang ZD; Long Y; Tsai WB; Fu S; Kurzrock R; Gagea-Iurascu M; Zhang F; Chen HH; Hennessy BT; Mills GB; Savaraj N; Kuo MT
Mol Cancer Ther; 2012 Nov; 11(11):2483-94. PubMed ID: 22914438
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy.
Ma K; Xu W; Wang C; Li B; Su K; Li W
Cancer Biomark; 2017; 18(3):297-303. PubMed ID: 27983538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
